GILD Gilead Sciences, Inc.

64.56
+0.25  (0%)
Previous Close 64.31
Open 64.50
Price To book 4.11
Market Cap 84.36B
Shares 1,306,728,000
Volume 5,659,024
Short Ratio 1.35
Av. Daily Volume 7,864,620

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 17854997
  2. 8-K - Current report 17839218
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828073
  4. 8-K - Current report 17804981
  5. CT ORDER - Confidential treatment order 17759473

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Filgotinib
Ulcerative Colitis
Phase 3 ongoing.
Filgotinib
Crohn's Disease
Phase 3 ongoing.
Filgotinib
Rheumatoid Arthritis
Phase 3 futility analysis 3Q 2017.
GS-5745
Gastric Cancer
Phase 3 trial initiated.
F/TAF
Pre exposure prophylaxis
Phase 3 data due mid-2017 with possible NDA filing 3Q 2017.
Bictegravir/F/TAF
HIV/AIDS
Phase 3 planned.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 3 planned.
Selonsertib (GS-4997)
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 4Q 2017.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 3Q 2017.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Phase 3 planned.
Entospletinib
Acute Myeloid Leukemia
Announced NDA filing December 8, 2016.
Sofosbuvir/Velpatasvir/Voxilaprevir
Hepatitis C virus (HCV)